Allergan stops sale of textured breast implants in Europe, shares sink

By Ankur Banerjee and Michael Erman NEW YORK (Reuters) - Drugmaker Allergan Plc said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered a recall of the implants, which have been linked to a rare form of cancer.

Reuters December 20, 2018 01:05:34 IST
Allergan stops sale of textured breast implants in Europe, shares sink

Allergan stops sale of textured breast implants in Europe shares sink

By Ankur Banerjee and Michael Erman

NEW YORK (Reuters) - Drugmaker Allergan Plc said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered a recall of the implants, which have been linked to a rare form of cancer.

Allergan defended the safety of its breast implants, but its shares fell 7.4 percent to $135.94 on Wednesday as some Wall Street analysts questioned whether the company would have to face any future product liability costs.

France's National Agency for the Safety of Medicines & Health Products (ANSM) said late on Tuesday that it was recalling Allergan's Microcell and Biocell textured breast implants because its safety certification had not been renewed by another agency.

Textured breast implants, which have a rough surface and are more commonly used in Europe than in the United States, have been linked to a rare type of cancer known as anaplastic large cell lymphoma.

As of Sept. 30, 2017, the U.S. Food and Drug Administration had received https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm481899.htm a total of 414 medical device reports of breast implant-associated anaplastic large cell lymphoma, including nine deaths. Of those the FDA, in a notice in August, said 272 reports included surface information on the implants, with 242 being of the textured variety.

The FDA did not immediately respond to request for comment on Wednesday.

The French agency said it has not identified any immediate health risk for the women who have received the implants. ANSM, which has been studying the health effects of breast implants since 2015, recommended in November that medical professionals use smooth implants instead. That followed a previous warning about risks related to the textured implants.

Allergan said the recall in Europe was not based on any new scientific evidence.

Textured implant sales in Europe are expected to be about $60 million in 2018, Allergan said. Suspension of sales in Europe does not affect implant sales in the United States, the company said.

While the financial impact is minimal, this is not helpful for the stock at a time the company is facing concerns over incremental competition for its top-selling Botox wrinkle treatment and is likely to face generic rivals to its Restasis eye drug over the near term, Citi analyst Liav Abraham said.

Products licensed for sale in the EU receive a "CE mark" by a body called GMED, certifying their safety among other things. The CE mark for the Allergan products expired on Sunday, and the ANSM asked for the recall.

The company said marketing of its smooth implants, whose CE mark was renewed, would not be affected.

Allergan said it will withdraw any remaining supply of the textured implants in Europe and is fully cooperating with the French authority.

Several plastic surgery websites say that the textured implants stay in place better than smooth versions, but also have a higher incidence of leaking.

(Reporting by Sudip Kar-Gupta in Paris, Saumya Sibi Joseph in Bengaluru and Michael Erman and Ankur Banerjee in New York, Editing by Maju Samuel, David Gregorio and Bill Berkrot)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Oil rises 2% as OPEC complies with production cuts
Business

Oil rises 2% as OPEC complies with production cuts

By Jessica Resnick-Ault NEW YORK (Reuters) - Oil prices strengthened on Wednesday, as OPEC and its allies were seen complying with a pact to cut oil supply in September, even as concerns loomed that recovery in fuel demand will be stalled by soaring global coronavirus cases. Early in the day crude was boosted by a bullish stock market. Even as equities whipsawed on pandemic worries, oil stayed higher, buoyed by expectations that OPEC could staunch a supply glut

Tesla's back-to-back price cuts bring sticker on U.S. Model S below $70,000
Business

Tesla's back-to-back price cuts bring sticker on U.S. Model S below $70,000

By Tina Bellon and C Nivedita (Reuters) - Tesla Inc will further cut the price of its Model S "Long Range" sedan in the United States to $69,420, the electric carmaker's chief executive, Elon Musk, announced in a tweet https://bit.ly/2H0JCP0 on Wednesday. The anticipated drop marks the second time this week Tesla has cut the price for the high-end sedan, following a 4% cut of the Model S's price in the United States on Tuesday to $71,990.

Trump cites teenaged son's bout with coronavirus in calling for schools to reopen
World

Trump cites teenaged son's bout with coronavirus in calling for schools to reopen

By Jeff Mason DES MOINES, Iowa (Reuters) - Under siege over his handling of the novel coronavirus pandemic, President Donald Trump on Wednesday cited what he said was his son's mild bout of the virus as a reason why American schools should reopen as soon as possible. Trump made the comment about his son, Barron, as the president swept into Iowa on a mission to shore up support in battleground states that he won in 2016 but is in danger of losing to Democrat Joe Biden barely three weeks before the election. First lady Melania Trump announced in a statement earlier in the day that the virus that struck both her and her husband had also infected their 14-year-old son